Shanghai Huilun Biotechnology Co., Ltd. announced a private placement of common shares for the gross proceeds of CNY 102 million on October 28, 2022. The transaction will include participation from Guiyang Xintian Pharmaceutical Co.,Ltd for CNY 30 million and include other investors. The transaction has been approved in the 5th session of the company's 7th directorate and the 4th session of the company's 7th supervisory board and is subject to approval by shareholders of the company.

After the capital increase, the Guiyang Xintian Pharmaceutical Co.,Ltd .cumulative investment amount in Huilun Pharmaceutical is CNY 320 million, the stake of the Guiyang Xintian Pharmaceutical Co.,Ltd. in the company will increase from 14.8810% to 15.3748%.